SCHEMBL4673573

SCHEMBL4673573

O=C(O)/C(O)=C/C(=O)c1ccc(Cc2cccc(F)c2)o1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR4A1 P22736 1/20 0.41
NR4A2 P43354 1/20 0.41
NR4A3 Q92570 1/20 0.41
ALDH1A1 P00352 3/20 0.41
MAPT P10636 1/20 0.41
HCAR2 Q8TDS4 2/20 0.40
LMNA P02545 3/20 0.39
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
THRB P10828 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
POLB P06746 2/20 0.38
TP53 P04637 2/20 0.38
GPR52 Q9Y2T5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673578 1.00 NR4A1 (0.41) NR4A1NR4A2NR4A3ALDH1A1MAPT
SCHEMBL755174 0.85 MAPT (0.38) ALDH1A1MAPTLMNAHPGDL3MBTL1
SCHEMBL755173 0.85 MAPT (0.38) ALDH1A1MAPTLMNAHPGDL3MBTL1
SCHEMBL755067 0.85 HTT (0.39) ALDH1A1MAPTLMNAMEN1KMT2A
SCHEMBL755066 0.85 HTT (0.39) ALDH1A1MAPTLMNAMEN1KMT2A
SCHEMBL4673991 0.80 GPR52 (0.41) NR4A1NR4A2NR4A3MAPTHCAR2
SCHEMBL4673996 0.80 GPR52 (0.41) NR4A1NR4A2NR4A3MAPTHCAR2
SCHEMBL4674457 0.80 HCAR2 (0.40) NR4A2MAPTHCAR2LMNASMN1; SMN2
SCHEMBL4674460 0.80 HCAR2 (0.40) NR4A2MAPTHCAR2LMNASMN1; SMN2
SCHEMBL4674508 0.78 ALDH1A1 (0.46) NR4A1NR4A2NR4A3ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 NR4A1 66/4885NR4A2 454/4885NR4A3 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.